I understand that management does not care about the stock price. The outcome of the trial is the only thing that matter. But to see the price in this company back at the capital raise level implies a lot.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025